United States · FDA National Drug Code directory
Tazorac
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 16110-833_7e6df473-8f69-4d67-bd06-a24f35ab0a62
- Product NDC
- 16110-833
- Form
- GEL
- Composition / generic term
- tazarotene
- Labeler
- Almirall, LLC
- Marketing category
- NDA
- Marketing start / end (source format)
- 20200221
- Source listing expiry
- 20261231
Source-listed ingredients
- TAZAROTENE — .5 mg/g
These values do not establish equivalence or a dose recommendation.
Packages
- 1 TUBE in 1 CARTON (16110-833-10) / 100 g in 1 TUBE · 16110-833-10
- 1 TUBE in 1 CARTON (16110-833-30) / 30 g in 1 TUBE · 16110-833-30
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →